Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-REL Antibody (R2C52)

Catalog #:   RHG03201 Specific References (50) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: IP, WB
Accession: Q04864
Overview

Catalog No.

RHG03201

Species reactivity

Human

Host species

Rabbit

Isotype

IgG

Clonality

Monoclonal

Tested applications

IP: 1:20, WB: 1:500-1:1000

Target

REL, Proto-oncogene c-Rel

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q04864

Applications

IP, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.

Clone ID

R2C52

Data Image
  • Western blot
    Western blot analysis of c-Rel in Hela, A549, HL-60 lysates using c-Rel antibody.
References

Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer., PMID:40136373

Joint analysis of the nPOD-Virus Group data: the association of enterovirus with type 1 diabetes is supported by multiple markers of infection in pancreas tissue., PMID:40090994

MIP-3α-antigen fusion DNA vaccine enhances sex differences in tuberculosis model and alters dendritic cell activity early post vaccination., PMID:39877094

NF-kB p65 and NF-kB p50 of the Rel Family. A Comparison between Irritable Bowel Syndrome and Inflammatory Bowel Disease Patients., PMID:39553363

Identification of alemtuzumab-suitable multiple sclerosis patients in Slovakia and sequencing of post-alemtuzumab immunomodulatory treatment., PMID:39494112

Identification of two novel variants, c.-35A>T and c.[-35A>T, 725T>G], in the FUT1 gene in a patient exhibiting the para-Bombay phenotype., PMID:39473114

Complete Remission with Inotuzumab Ozogamicin as Fourth-Line Salvage Therapy in a Child with Relapsed/Refractory Acute Lymphoblastic Leukemia., PMID:39449299

Type-Specific Impacts of Protein Defects in Pathogenic NFKB2 Variants: Novel Clinical Findings From 138 Patients., PMID:39447838

NrCAM activates the NF-κB signalling pathway by competitively binding to SUMO-1 and promotes Th17 cell differentiation in Graves' disease., PMID:39155774

Direct observation correlates NFκB cRel in B cells with activating and terminating their proliferative program., PMID:39024115

RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer., PMID:38345769

Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas., PMID:38331870

Metformin targets intestinal immune system signaling pathways in a high-fat diet-induced mouse model of obesity and insulin resistance., PMID:37795356

The regulatory effect of NF-κB signaling pathway on biomineralization and shell regeneration in pearl oyster, Pinctada fucata., PMID:37739291

Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment., PMID:37474523

T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions., PMID:37465110

Toll-like receptor mediated inflammation directs B cells towards protective antiviral extrafollicular responses., PMID:37407556

Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy., PMID:37337107

Sortilin Inhibition Protects Neurons From Degeneration in the Diabetic Retina., PMID:37272764

Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia., PMID:37221877

Pre-Clinical Autoimmunity in Lupus Relatives: Self-Reported Questionnaires and Immune Dysregulation Distinguish Relatives Who Develop Incomplete or Classified Lupus From Clinically Unaffected Relatives and Unaffected, Unrelated Individuals., PMID:35720322

Disaccharide-tag for highly sensitive identification of O-GlcNAc-modified proteins in mammalian cells., PMID:35604954

Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel., PMID:34945004

Induction of Foxp3 and activation of Tregs by HSP gp96 for treatment of autoimmune diseases., PMID:34877502

Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma., PMID:34780623

COVID-19 - prime time for microphysiological systems, as illustrated for the brain., PMID:34698363

Transcription factor c-Rel mediates communication between commensal bacteria and mucosal lymphocytes., PMID:34622991

Targeting NF-κB c-Rel in regulatory T cells to treat corneal transplantation rejection., PMID:34254428

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma., PMID:34170745

T and B Lymphocyte Transcriptional States Differentiate between Sensitized and Unsensitized Individuals in Alpha-Gal Syndrome., PMID:33804792

Characteristics of COVID-19 Patients Based on the Results of Nucleic Acid and Specific Antibodies and the Clinical Relevance of Antibody Levels., PMID:33585558

Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial., PMID:33403697

AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys., PMID:32886754

IκBα Nuclear Export Enables 4-1BB-Induced cRel Activation and IL-2 Production to Promote CD8 T Cell Immunity., PMID:32817348

cRel expression regulates distinct transcriptional and functional profiles driving fibroblast matrix production in systemic sclerosis., PMID:32725139

[Analysis of fatality rates case of SARS-CoV-2 infection in the Autonomous Communities of Spain]., PMID:32709574

A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma., PMID:32631655

IL-21 and IL-5 coordinately induce surface IgA+ cells., PMID:32492473

Inhibition of IL-2 or NF-κB Subunit c-Rel-Dependent Signaling Inhibits Expansion of Regulatory T Cells During Acute Friend Retrovirus Infection., PMID:32315584

Genome-wide interaction screen for Mycobacterium tuberculosis ClpCP protease reveals toxin-antitoxin systems as a major substrate class., PMID:32301575

BCR-Induced Ca2+ Signals Dynamically Tune Survival, Metabolic Reprogramming, and Proliferation of Naive B Cells., PMID:32294437

Catcher in the rel: Nanoparticles-antibody conjugate as NF-κB nuclear translocation blocker., PMID:32247937

miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids., PMID:32210951

c-Rel gain in B cells drives germinal center reactions and autoantibody production., PMID:32191641

Treating Autoimmune Diseases by Targeting IL-23 with Gene-Silencing Pyrrole-Imidazole Polyamide., PMID:32169850

Regulation of B-cell function by NF-kappaB c-Rel in health and disease., PMID:32130429

The NF-κB transcription factor c-Rel controls host defense against Citrobacter rodentium., PMID:31724737

Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network., PMID:31378966

A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC)., PMID:31272883

Responsiveness of chronic lymphocytic leukemia cells to B-cell receptor stimulation is associated with low expression of regulatory molecules of the nuclear factor-κB pathway., PMID:31097630

Datasheet

Document Download

Anti-REL Antibody (R2C52).pdf

 

$ 290
Product specifications
50 μg 290 100 μg 484

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-REL Antibody (R2C52) [RHG03201]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only